Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire HilleVax (NASDAQ: HLVX). The acquisition terms included $1.95 per share in cash plus one non-tradeable contingent value right (CVR).
The tender offer expired on September 15, 2025, with 39,214,689 shares validly tendered, representing approximately 77.48% of HilleVax's outstanding shares. Following the merger completion, HilleVax became a wholly owned subsidiary of XOMA Royalty. HilleVax shares will cease trading on Nasdaq as of September 17, 2025, and will be delisted and deregistered.
XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership team, including CEO Owen Hughes and CIO Brad Sitko, will deliver a company update presentation on Monday, September 8, 2025, at 9:00 AM ET.
Investors can access the presentation through a webcast link or via the investor relations section of XOMA's website at www.xoma.com.
XOMA Royalty (NASDAQ:XOMA) has announced its subsidiary XRA 5 Corp. will acquire Mural Oncology (NASDAQ:MURA) in an all-cash transaction valued at approximately $36.2 million. Under the agreement, Mural shareholders will receive a base price of $2.035 per share, with potential for an additional $0.205 per share based on Mural's closing net cash position.
The base offer represents a 13.1% premium to Mural's closing price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed price of $1.03 on April 14, 2025. The acquisition, recommended by Mural's board, follows a strategic review process and is expected to close by the end of 2025, subject to shareholder and regulatory approvals.
XOMA Royalty (NASDAQ:XOMA) reported Q2 2025 financial results and significant business developments. The company received $29.6 million in royalties and milestones in H1 2025, including $11.7 million in Q2. Notable achievements include the acquisition of multiple companies (Turnstone Biologics, LAVA Therapeutics, and HilleVax) and the $20 million purchase of mezagitamab royalty rights from BioInvent.
Q2 2025 financial highlights include net income of $9.2 million and total income/revenue of $13.1 million. The company ended Q2 with $78.5 million in cash and cash equivalents. Several pipeline advancements were reported, including Rezolute's completion of Phase 3 enrollment for ersodetug and EMA's acceptance of Day One's tovorafenib MAA.
[ "Received $29.6 million in royalties and milestones in H1 2025", "Net income of $9.2 million in Q2 2025, up from $7.4 million in Q2 2024", "Strategic acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax expanding portfolio", "Strong cash position of $78.5 million as of June 30, 2025", "Multiple pipeline advancements including regulatory milestones and Phase 3 trial progress", "Decreased G&A expenses to $7.8 million in Q2 2025 from $11.0 million in Q2 2024" ]XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire Turnstone Biologics (NASDAQ: TSBX). The deal terms included $0.34 per share in cash plus one non-tradeable contingent value right (CVR).
As of the expiration date on August 7, 2025, 17,192,002 shares were validly tendered, representing approximately 74% of Turnstone's outstanding shares. Following the tender offer, XOMA Royalty merged Turnstone with its subsidiary XRA 3 Corp., making Turnstone a wholly owned subsidiary. Turnstone's shares will cease trading on Nasdaq as of August 11, 2025, and will be delisted and deregistered.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive agreement to acquire LAVA Therapeutics (NASDAQ: LVTX) in a structured deal valued at $1.16 to $1.24 per share in cash, plus a contingent value right (CVR). The CVR entitles shareholders to 75% of net proceeds from LAVA's partnered assets and potential out-licensing of unpartnered programs.
The transaction, expected to close in Q4 2025, requires at least 80% shareholder tender and includes specific closing conditions. As part of the deal, LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. The acquisition adds milestone and royalty economics from LAVA's gamma delta bispecific antibodies portfolio to XOMA Royalty's assets.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive merger agreement to acquire HilleVax (NASDAQ: HLVX) in a deal that values HilleVax shares at $1.95 in cash per share plus a contingent value right (CVR).
The CVR includes potential additional payments from: (1) excess cash above $102.95 million, (2) 90-100% of savings from Boston office lease obligations, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has secured support from 22.9% of HilleVax stockholders, including officers and directors.
XOMA Royalty will commence a tender offer by August 18, 2025, with the acquisition expected to close in September 2025. The deal requires a majority of HilleVax shares to be tendered and maintaining a minimum cash balance at closing.
ESSA Pharma (NASDAQ: EPIX) has announced a definitive agreement to be acquired by XenoTherapeutics, with financing from XOMA Royalty Corporation (NASDAQ: XOMA). The all-cash transaction will provide EPIX shareholders with approximately $1.91 per common share, plus one non-transferable contingent value right (CVR) worth up to $0.06 per share payable within 18 months post-closing.
The transaction, expected to close in second half of 2025, requires approval from 66⅔% of ESSA shareholders and securityholders. The agreement includes a $2.5 million termination fee and customary deal-protection provisions. ESSA's board unanimously approved the transaction, with directors and senior officers, holding 2.23% of shares, agreeing to vote in favor.
[ "All-cash transaction providing immediate liquidity to shareholders", "Additional potential value through CVR of up to $0.06 per share", "Expedited cash distribution process compared to standard liquidation", "Unanimous board approval and management support with 2.23% commitment" ]XOMA Royalty (NASDAQ:XOMA) has announced a definitive merger agreement to acquire Turnstone Biologics (NASDAQ-CM:TSBX). Under the terms of the agreement, XOMA will pay $0.34 in cash per share plus one non-transferable contingent value right (CVR) for each Turnstone share.
The acquisition will proceed through a tender offer starting by July 11, 2025, requiring a majority of outstanding shares to be tendered and meeting certain conditions including minimum cash balance requirements. Approximately 25.2% of Turnstone stockholders have already agreed to tender their shares. The merger is expected to close in August 2025.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
